R. Salazar

发表

Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects

J. Benítez, Á. Carracedo, A. Osorio, 2003, Human mutation.

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

M. Urioste, J. Benítez, I. Chirivella, 2009, Breast Cancer Research and Treatment.

BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain.

R. González-Sarmiento, R. Salazar, C. Rodríguez, 2006, Cancer letters.

γ-Heregulin has no biological significance in primary breast cancer

R. González-Sarmiento, R. Salazar, M. Abad, 2002, British Journal of Cancer.

Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information

J. Benítez, R. Milne, A. Osorio, 2007, Human mutation.

The variant E233G of the RAD51D gene could be a low‐penetrance allele in high‐risk breast cancer families without BRCA1/2 mutations

Pilar Zamora, Trinidad Caldés, Ana Osorio, 2004, International journal of cancer.

Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer.

J. Benítez, Á. Carracedo, A. Osorio, 2006, Clinical chemistry.

The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain

M. Urioste, J. Benítez, A. Antoniou, 2008, Clinical Cancer Research.

The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

M. Urioste, J. Benítez, A. Antoniou, 2008, Clinical Cancer Research.